STAAR SURGICAL ($NASDAQ:STAA) reported total revenue of USD 92.3 million for the quarter ending June 30 2023, an increase of 13.8% from the same quarter in the previous year. However, net income for the period was USD 6.1 million, a decrease of 53.5% from the same quarter in the prior year.
GoodWhale conducted an analysis of STAAR SURGICAL‘s wellbeing and, according to the Star Chart, STAAR SURGICAL has a high health score of 10/10 in terms of its cashflows and debt. This allows them to safely ride out any crisis without the risk of bankruptcy. The type of investor that may be interested in such a company would be those looking for strong assets, growth, and profitability. While STAAR SURGICAL may not be the best option for investors looking for dividends, it still offers a solid opportunity for those looking for above-average returns. Furthermore, STAAR SURGICAL’s strong assets and competitive advantage make it a relatively safe investment for those looking to mitigate risk. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Staar Surgical. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Staar Surgical. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Staar Surgical. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Staar Surgical are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Its competitors are Atrion Corp, Implanet SA, Edwards Lifesciences Corp.
Atrion Corporation is a medical device company that develops and manufactures products for use in cardiovascular, ophthalmology, and renal applications. The company has a market cap of 1.1 billion and a return on equity of 9.79%. Atrion’s products are used in procedures such as cardiac surgery, cataract surgery, and dialysis. The company’s products are sold in over 50 countries worldwide.
Implanet SA is a medical device company that designs, develops, and markets orthopedic implants for the treatment of spine pathologies and trauma. As of 2022, Implanet SA has a market cap of 5.32M and a Return on Equity of -114.56%. The company’s products are used in the treatment of degenerative diseases, deformities, tumors, and trauma.
– Edwards Lifesciences Corp ($NYSE:EW)
Edwards Lifesciences Corp is a global leader in cardiovascular care, helping people live longer, healthier lives. The company’s products and technologies are used by healthcare professionals to treat some of the most serious and life-threatening cardiovascular conditions. Edwards Lifesciences has a market cap of 42.38B as of 2022 and a ROE of 18.9%. The company’s products are used by healthcare professionals to treat cardiovascular conditions such as heart failure, valve disease, and sepsis.
STAAR SURGICAL, a publically-traded company, reported total revenue of USD 92.3 million for the quarter ending June 30 2023, representing an increase of 13.8% from the same period in the prior year. However, the company’s net income for the period was USD 6.1 million, a decrease of 53.5% compared to the same quarter in the prior year. Investing analysis of STAAR SURGICAL suggests that while the company is generating increased revenue, their net income is taking a hit due to higher operational costs. Investors should consider this when making decisions about whether or not to invest in STAAR SURGICAL.